The Joe Rogan ExperienceJoe Rogan Experience #2477 - Rick Perry & W. Bryan Hubbard
Joe Rogan and Rick Perry on texas commits $100M to ibogaine FDA trials for addiction, trauma.
In this episode of The Joe Rogan Experience, featuring Joe Rogan and Joe Rogan, Joe Rogan Experience #2477 - Rick Perry & W. Bryan Hubbard explores texas commits $100M to ibogaine FDA trials for addiction, trauma Hubbard reports Texas will invest $100 million to fund the Texas Ibogaine Initiative, aiming to run a unified FDA drug-development trial and accelerate ibogaine toward approval for addiction and trauma-related conditions.
At a glance
WHAT IT’S REALLY ABOUT
Texas commits $100M to ibogaine FDA trials for addiction, trauma
- Hubbard reports Texas will invest $100 million to fund the Texas Ibogaine Initiative, aiming to run a unified FDA drug-development trial and accelerate ibogaine toward approval for addiction and trauma-related conditions.
- The guests argue ibogaine uniquely “interrupts” substance dependence (opioids, alcohol, stimulants, nicotine) and may support recovery from PTSD/TBI and other neurological disorders, citing open-label history, a Stanford veteran study, and anecdotal cases.
- Rick Perry explains his shift from traditional anti-drug politics to psychedelic advocacy through firsthand exposure to veterans’ suicidality and addiction, framing the effort as a moral obligation to warfighters and families harmed by the opioid crisis.
- They outline an expanding national political coalition—multiple states and tribal nations proposing legislation/appropriations—to partner with Texas and pressure federal agencies to reschedule ibogaine and allow broader access pathways.
- The conversation widens into critiques of the War on Drugs, pharmaceutical incentives, bureaucratic inertia, and a spiritual framing that psychedelics can catalyze personal meaning-making and social cohesion in an era of technological change.
IDEAS WORTH REMEMBERING
7 ideasTexas is positioned as the national hub for ibogaine drug development.
Hubbard says Texas moved from a proposed $50M public-private plan to a fully state-funded $100M effort to run a unified FDA pathway, intended to become the centerpiece trial other states can join.
Political persuasion hinged on veteran testimonies and “nonpartisan” public health framing.
The Luttrell brothers’ personal ibogaine stories are presented as pivotal in opening Texas leadership to the initiative, shifting the narrative from counterculture drug politics to warfighter care and crisis response.
The guests claim ibogaine’s standout value is rapid disruption of physiological dependence.
They repeatedly emphasize a 48–72 hour withdrawal/interruption window and contrast it with long abstinence timelines, arguing this makes ibogaine categorically different from standard addiction treatment (while acknowledging unpleasant acute effects).
Brain-health claims are central but remain scientifically contested and a key reason for large trials.
Perry shares his own imaging anecdotes (improved prefrontal activity; reduced atrophy), and they cite Stanford vet work; they argue rigorous, longitudinal neuroimaging studies are needed to validate mechanisms, durability, and who benefits.
A multi-state strategy is designed to bypass federal inertia and force coordinated FDA engagement.
They describe recruiting legislators across many states, using model bills and appropriations to create an “unstoppable external force” that funds and politically supports one trial rather than fragmented efforts.
Regulatory leverage points include rescheduling and Right-to-Try interpretation.
They argue ibogaine does not fit Schedule I criteria (non-addictive, medical potential) and claim DEA is improperly excluding Schedule I drugs from Right-to-Try; they call for executive action and agency directives to accelerate access after Phase 1.
The movement mixes medical claims with an explicit spiritual/values narrative.
Hubbard and Perry assert ibogaine (and psychedelics broadly) can catalyze meaning, reduce despair, and affirm “human divinity,” and they position this as culturally strategic—especially for skeptical religious/conservative audiences.
WORDS WORTH SAVING
5 quotesI can confirm that the great state of Texas is going to fully fund... a full $100 million to launch the development of Ibogaine all the way through the FDA's drug development process.
— W. Bryan Hubbard
Their lives are not worth more than my reputation.
— Rick Perry
Ibogaine fits neither of those. Ibogaine is not an addictive compound... It's also absolutely not a recreational compound.
— Rick Perry / Joe Rogan
You can get eighty-five percent of the people who are hooked on opioids clean in seventy-two hours.
— Rick Perry
This is an emancipation movement for the mind, body, and soul of every human being... lethally estranged from their own spirituality.
— W. Bryan Hubbard
QUESTIONS ANSWERED IN THIS EPISODE
5 questionsWhat specifically will Texas’ $100M fund (Phase 1/2/3 design, endpoints, sites, timelines), and who will run the trial operationally?
Hubbard reports Texas will invest $100 million to fund the Texas Ibogaine Initiative, aiming to run a unified FDA drug-development trial and accelerate ibogaine toward approval for addiction and trauma-related conditions.
Which published, peer-reviewed human studies best support the “48–72 hour interruption” and “two-dose ~98%” claims, and what are the limitations of that evidence?
The guests argue ibogaine uniquely “interrupts” substance dependence (opioids, alcohol, stimulants, nicotine) and may support recovery from PTSD/TBI and other neurological disorders, citing open-label history, a Stanford veteran study, and anecdotal cases.
Ibogaine carries known cardiac risks (e.g., QT prolongation): what exact safety protocols, screening criteria, and emergency capabilities will the Texas trial require?
Rick Perry explains his shift from traditional anti-drug politics to psychedelic advocacy through firsthand exposure to veterans’ suicidality and addiction, framing the effort as a moral obligation to warfighters and families harmed by the opioid crisis.
How will the initiative prevent “clinic gold rush” dynamics—unregulated domestic offerings, adulterated supply, or coercive/unsafe settings—while access remains constrained?
They outline an expanding national political coalition—multiple states and tribal nations proposing legislation/appropriations—to partner with Texas and pressure federal agencies to reschedule ibogaine and allow broader access pathways.
If DEA rescheduling doesn’t happen, what is the realistic pathway to FDA approval and post-approval access given Schedule I manufacturing, transport, and prescribing barriers?
The conversation widens into critiques of the War on Drugs, pharmaceutical incentives, bureaucratic inertia, and a spiritual framing that psychedelics can catalyze personal meaning-making and social cohesion in an era of technological change.
EVERY SPOKEN WORD
Install uListen for AI-powered chat & search across the full episode — Get Full Transcript
Get more out of YouTube videos.
High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.
Add to Chrome